Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As of February 2021 Abbott Laboratories has a market cap of $216.79
Roche (RHHBY) Market cap: $280.39 B. As of February 2021
thermo fisher market cap February 19, 2021 is $189.79B
Avacta is in a position to help shape the future of medicine through powerful new anti-cancer treatments and diagnostics. With appropriate scale-up capital, Avacta will become a multi-billion-dollar life sciences company competing globally with the likes of Roche-Genentech, Thermo-Fisher and Abbott.
Alastair Smith, CEO of Avacta sharebuyers 27th october 2020
Spartacus one of them was a little company called Roche
The only thing ill do at £20.00 is take a little slice for luxurys
If you got in hear at 1/2 pound and ride it to £20 why would you leave then unless you need the money ?
If that was the case you might as well go at £5 /£7.50 thats a good return on any stock so cheerio
As mentioned 3 or 4 pharmas that he wants to compete with, i dont recall there names but i am pretty suure they were in the 150/ 250 billion mcap range, thats what he has desighns on and thats a goal
So again who ever thinks he would sell out for 20/50 billion is deluded imop
This company and its boss are fabulous and i will deffend it form all quarters
Easyiest share to be invested in, just sit on your hands and let it grow
That’s just doxcurubicon. Then the rest of the chemo drugs pipeline following on and everything else.
It’s a personal view on whether you think they’ll work and to what extent. If they do it’ll be enormous and hard to say what multiples you’d apply to the revenues X20/30/40?
I think the amount of times the word “if” crops up in that post probably tells you why the majority of PI’s would absolutely snap your hand off at the prospect of £20 a share!
10 x currennt share price = 5 billion mcap that is absolutly chicken feed with avactas potential over the next 3/5 + years
If the clinical trials perform we will be looking at 100 x mcap without any problems for starters imop
If the covid lft performs gold standard, putting avacta in the driving seat with heavy sales 2/3 years minimum
Solidifiying avacta as a testing giant most likely bringing out new tests for many other disease's/conditions
Setting us up nicely for a nice steady revenue from testing alone, that will putva big dent in the 5 billion mcap alone
What happens if the doxcurubicon trial goes to plan
Currently a 1 billion market, that could be double tripled
If we got 1/3 of that, on a drug thats been around 40/50 years, then how many years multiple would you use for that ? 5/10
All pie in the sky till proven, but if....IF it is proven then theres atleast another half dozen cancer drugs that would like the same treatment, 3 already lined up on possible sucess
So anyone thinking that 20/50 /200 + is a fantasy might need to do more reasearch unless they want to sell them selves short
Also i cant imagine As letting his company go for 5/10/20 billion hes not stupid, is it rampy know i dont think so lets see how she goes the next 3/5 years cause i aint going any whare gla
Sorry for the DYS
£7 sp means my SIPP is over £1m but if the talk here is £20 + then???!!!???
Agreed Sage. Also will not be our decision to make as small fry!!
Agreed Sage. Also will not be our decision to make as small fry!!
I’m hugely over invested here but you’ve gotta laugh at those saying they wouldn’t take an offer of > 10 times the current share price...
Certainly huge potential here but come on....
possible share price if we are part of operation moonshot with 50-60 million capacity courtesy of UK govt? Anyone like to throw in an educated guess
This happened to me with my Green King shares. I can't remember the figures, but there was an offer for takeover that equalled almost double the share price. The share price quickly rose, as others have noted, it depends on supply and demand, and the perceived chance of the offer being accepted.
The offer was then voted on by the shareholders, in that case, it was accepted, and my shares were bought of me for the offer price.
Hope that helps.
I wouldn’t take £20. 3/4 years on it could be more than 10 times higher if the AVA6000 works. We’ll know a long way before then if it’s successful, possibly even end of this year.
I don’t think it would be easy to find another opportunity like this in my lifetime.
All big companies start as small companies and Avacta are now extremely well positioned to start the journey to giant status.
I too will be in this for the long run these opportunities don't come alone too often and must be grasped with both hands.
If we get to £20, it’s on the back of impressive LFT sales, and some oncology success. But won’t be all. AVA only. Therefore, only the start.
£50 is where a bid would be looked at, in my opinion. But I’d hope not.
All very positive, but LOTS yet to align. It’s where the value could realistically be, given the markets we are targeting. They all print money.
If we get offered £20 per share, I’ll be using my shares to vote against it.
I will be looking for more than that, and the longer we stay independent the closer we get to £200 (ex Chy-nah) which may seem ridiculous now, but having been in this share since last April and read everything about it, is definitely an outside possibility in a few years time.
Ps I have never seen this board as quiet (and lacking any negativity) since I bought in 10 months ago!
Bodes well for this month (fingers crossed emoji).
And the bloke who resigned in 2001
Optimism wont help us! what about the II investment in 2006!! where is QD's incredible research, we are all doomed I tell you doomed............................
Bit of a novice question im afraid.
If a takeover does occur are we forced to sell our shares?
or do we keep them and the share prices is then dictated by the takeover price?
Apologies if this makes no sense
Never known optimism like it on here this weekend. How are we going to bat away the many offers for the company and how can I cope with having millions in my accounts... :-D
Tough times...
Sometimes you will see sp going higher than the offer price in anticipation of a bidding war starting
Thanks PL I sort of guessed that but have not been in that position